FDMT vs LIN · rev $37.0K vs P/E 34, rev $33.99B
4D Molecular Therapeutics Inc (FDMT) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
FDMT currently screens at market cap $518.1M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the FDMT and LIN stock pages for the full models.
Not investment advice.